DocMorris AG (OTCMKTS:ZRSEF – Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 643,190 shares, an increase of 724.0% from the June 30th total of 78,057 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
DocMorris Stock Performance
DocMorris stock opened at $7.45 on Friday. The company’s 50 day moving average is $7.45 and its two-hundred day moving average is $7.45. DocMorris has a 52-week low of $7.45 and a 52-week high of $42.50.
Analyst Ratings Changes
A number of brokerages recently issued reports on ZRSEF. UBS Group raised DocMorris from a “sell” rating to a “neutral” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft raised shares of DocMorris from a “hold” rating to a “buy” rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.
About DocMorris
DocMorris is a leading European online pharmacy brand and a subsidiary of the Swiss-based Zur Rose Group (OTCMKTS:ZRSEF). Through its digital platform, the company offers mail-order dispensing of prescription medications and over-the-counter health products directly to consumers’ homes.
The company’s core services include the online sale and delivery of prescription and non-prescription drugs, health supplements, personal care items and medical devices. Leveraging its e-commerce infrastructure and proprietary pharmacy management systems, DocMorris also provides digital health solutions such as telemedicine consultations, medication management tools and mobile app-based healthcare services.
Originally launched in the early 2000s in Germany, DocMorris has expanded its reach to serve customers in multiple European countries, including the Netherlands, Belgium, Luxembourg and Switzerland.
Featured Stories
- Five stocks we like better than DocMorris
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for DocMorris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocMorris and related companies with MarketBeat.com's FREE daily email newsletter.
